Examining Vascular Outcomes in COPD Inpatients (AIM 1) Examining Early Rehabilitation on Discharged COPD Patients (AIM 2)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01949727|
Recruitment Status : Recruiting
First Posted : September 24, 2013
Last Update Posted : May 2, 2018
|Condition or disease||Intervention/treatment|
|Chronic Obstructive Pulmonary Disease (COPD)||Other: AIM 2: Pulmonary Rehabilitation|
Show Detailed Description
|Study Type :||Observational|
|Estimated Enrollment :||100 participants|
|Official Title:||COPD Hospitalization:Examining Pulmonary and Cardiovascular Outcomes in Chronic Obstructive Pulmonary Disease Inpatients (AIM 1). COPD Rehabilitation:Examining the Impact of Early Pulmonary Rehabilitation on Discharged COPD Patients (AIM 2)|
|Study Start Date :||October 2013|
|Estimated Primary Completion Date :||March 2019|
|Estimated Study Completion Date :||September 2019|
AIM 1/AIM 2: AECOPD Admitted Patients
AIM 1:All patients admitted to the hospital (either to Pulmonary or General Medicine) will be recruited to enroll in this observational study. No specific intervention is planned for this group.
AIM 2: All patients admitted to the pulmonary ward for an AECOPD, including those who have completed Aim 1, will be offered participation into this arm of the study. Pulmonary rehabilitation will be conducted through the Breathe Easy Program at the Centre for Lung Health.
Other: AIM 2: Pulmonary Rehabilitation
Patients exercise 2 hours per session which includes aerobic exercise (20-40 minutes per session) as well as strength training. All exercise is carefully tracked by trained Respiratory or Physical Therapists. Patients also receive education from a multi-disciplinary team aimed at patient self-management.
- Inflammatory markers [ Time Frame: 14 days ]CRP: C-reactive protein is a non-specific serum marker of inflammation (range <8 is normal)
- Length of Stay (LOS) [ Time Frame: up to 30 days ]Length of stay in the hospital to the point where the patient is stable from the COPD perspective. Patients with LTC needs may stay beyond the designated hospitalization due to care needs.
- Inflammatory marker (IL-6) [ Time Frame: 14 days ]IL-6: is an interleukin that acts as both a pro-inflammatory and anti-inflammatory cytokine.
- Inflammatory marker (TNF-alpha) [ Time Frame: 14 days ]TNF-alpha
- Inflammatory Marker (MMP-2) [ Time Frame: 14 days ]MMP-2
- Quality of Life (QoL) [ Time Frame: 14 days ]CAT MMRC SGHRQ
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01949727
|Contact: Michael Stickland, PhDfirstname.lastname@example.org|
|Contact: Desi P Fuhr, MScemail@example.com|
|University of Alberta Hospital||Recruiting|
|Edmonton, Alberta, Canada, T6G 2B7|
|Contact: Desi P Fuhr, MSc 780-492-1121 firstname.lastname@example.org|
|Contact: Brian H Rowe, MD, MSc 780-407-6707` email@example.com|
|Sub-Investigator: Mohit Bhutani, MD, FRCPC|
|Sub-Investigator: Richard Leigh, MD, PhD|
|Sub-Investigator: Brian H Rowe, MD, MSc|
|Principal Investigator:||Michael Stickland, PhD||University of Alberta|